Advent Venture Partners appoints new bio-tech executive-in-residence(2)

Advent Venture Partners has hired Dr Richard Mason, a former senior vice-president at Cambridge Antibody Technology, as its executive-in-residence.

Dr Richard Mason, a biotechnologist previously with Cambridge Antibody Technology, is joining UK venture firm Advent Venture Partners to offer wide-ranging strategic advice on bio-tech businesses.

According to Mason as executive-in-residence he will help source and review deals. He said he would maximise and expand the Advent Ventures bio-tech portfolio, using his business and commercial expertise.

Mason co-founded online health business Cambridge Health Informatics, which he left to  join Cambridge Antibody Technology. During his time there, Richard led multiple transactions, including the negotiation of its joint antibody discovery and development collaboration with global pharma business AstraZeneca. This became the basis for a takeover in May 2006.

The acquisition by AstraZeneca led to Mason’s departure. He said his preference is to develop commercial potential for early stage and small bio-tech companies rather than for companies on the scale of conglomerates.

Advent Venture Partners invests in biopharmaceuticals as well as in software and communications technology.